This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

New Options, New Concerns

Karl Insogna, MD; John Concato, MD, MS, MPH; Janet Henrich, MD

JAMA. 1996;276(17):1430-1432.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

POSTMENOPAUSAL osteoporosis is due primarily to the accelerated bone loss that occurs in the years following menopause. Estrogen replacement effectively abrogates this increase in bone breakdown and appears to decrease fracture rates.^1-4 Despite the development of several promising alternatives, estrogen remains the standard for treatment of postmenopausal osteoporosis and the only drug with labeling approval for its prevention.⁵ Long-term adherence to oral hormone replacement therapy (HRT), however, is poor. In 1 recent study, fewer than 25% of women reported that they still used HRT 2 years after initiation of treatment.⁶ A practical limitation of HRT is that the intermittent administration of a progestational agent with estrogen to women with a uterus is accompanied by the return of regular uterine bleeding in nearly 75% of individuals.⁷ Many postmenopausal women find such bleeding unacceptable. An alternative regimen that employs the daily use of both a progestin and an . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?